Article
Gastroenterology & Hepatology
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Kento Inada, Koji Yamashita, Shuhei Sekiguchi, Yuka Hayakawa, Leona Osawa, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Namiki Izumi
Summary: In chronic hepatitis B patients, the PAGE-B score can be used for HCC risk assessment, especially at different time points during NA treatment. The predictive ability of mPAGE-B and REACH-B at 2 years after NA treatment is not as good as PAGE-B.
JOURNAL OF VIRAL HEPATITIS
(2021)
Article
Gastroenterology & Hepatology
Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S. Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson
Summary: A meta-analysis was conducted on clinical outcomes after nucleot(s)ide analogue (NA) discontinuation for HBeAg-negative CHB patients, revealing that virological relapse is common but clinical relapse occurs in only one-third of patients at 12 months post-NA discontinuation. Discontinuation of NA therapy can lead to HBsAg clearance, with higher rates observed with longer follow-up periods.
Article
Medicine, General & Internal
Julian Hercun, Theo Heller, Jeffrey S. Glenn, David E. Kleiner, Christopher Koh
Summary: This study evaluates the impact of nucleos(t)ide analogs on the histological appearance of chronic HDV infection and finds that patients on nucleos(t)ide analogs demonstrate a unique membranous staining pattern.
FRONTIERS IN MEDICINE
(2023)
Review
Health Care Sciences & Services
Yi-Chang Liu, Chi-Mu Hsu, Samuel Yien Hsiao, Hui-Hua Hsiao
Summary: With the increasing number of allo-HSCT globally and the prevalence of HBV infection, HBV reactivation post transplantation is a significant issue. Antiviral prophylaxis is crucial in reducing HBV replication and mortality, highlighting the importance of identifying high-risk patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Environmental Sciences
Ming Hui Li, Hui Hui Lu, Qi Qi Chen, Yan Jie Lin, Zhan Zeng, Yao Lu, Lu Zhang, Jian Ping Dong, Wei Yi, Yao Xie
Summary: During antiviral therapy, changes in cytokine levels were observed, with PEG-IFN showing significant decreases in certain cytokines and increases in others compared to ETV. PEG-IFN also had higher rates of HBeAg and HBsAg disappearance compared to ETV, indicating better immune control and functional cure.
BIOMEDICAL AND ENVIRONMENTAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Tao Li, Yan Liang, Meng Zhang, Feng Liu, Lixin Zhang, Baohua Yang, Lei Wang
Summary: The study aimed to evaluate the effects of consolidation therapy after discontinuation of nucleoside/nucleotide analogs (NAs) in HBeAg positive chronic hepatitis B (CHB) patients. Results showed that long-term consolidation therapy is generally safe and feasible in these patients, with a preference for a three-year consolidation period in clinical practice.
HEPATOLOGY RESEARCH
(2021)
Review
Medicine, General & Internal
Qian Zhang, Da-Chuan Cai, Peng Hu, Hong Ren
Summary: LLV is defined as persistent or intermittent detectable HBV DNA after 48 weeks of antiviral treatment, and even with long-term therapy, some patients still experience LLV; research on the impact of LLV on clinical outcomes is limited, and there are questions regarding the follow-up treatment for these patients.
CHINESE MEDICAL JOURNAL
(2021)
Article
Immunology
Jun Li, Xiao-Qin Dong, Li-Hua Cao, Zhan-Qing Zhang, Wei-Feng Zhao, Qing-Hua Shang, Da-Zhi Zhang, An-Lin Ma, Qing Xie, Hong-Lian Gui, Guo Zhang, Ying-Xia Liu, Jia Shang, Shi-Bin Xie, Yi-Qi Liu, Chi Zhang, Gui-Qiang Wang, Hong Zhao
Summary: This study investigated the factors associated with persistent viremia in patients with chronic hepatitis B receiving long-term antiviral therapy, and found that baseline HBV DNA level, Anti-HBc level, and HBeAg seropositivity were associated with persistent viremia.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Nutrition & Dietetics
Sheng-Jie Shiue, Chao-Ling Cheng, Han-Shiang Shiue, Chun-Nan Chen, Sheng-Wei Cheng, Li-Wei Wu, Ganbolor Jargalsaikhan, Tze-Sian Chan, Hsin-Yi Lin, Ming-Shun Wu
Summary: This study found that oral Arthrospira as an add-on therapy can reduce HBsAg levels in CHB patients and improve immune function by promoting the activation of B cells, T cells, and NK cells.
Article
Gastroenterology & Hepatology
Shun Kaneko, Masayuki Kurosaki, Kento Inada, Sakura Kirino, Yuka Hayakawa, Koji Yamashita, Leona Osawa, Shuhei Sekiguchi, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Jun Itakura, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Namiki Izumi
Summary: This study investigated the virological characteristics of HBcrAg in CHB patients and the factors associated with HCC risk in HBeAg-negative patients. Results showed that higher levels of HBcrAg in HBeAg-negative patients were associated with cirrhosis and higher HBV DNA levels, and were an independent predictive factor for HCC development in patients receiving NA therapy.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Zhanqing Zhang, Wei Lu, Dong Zeng, Dan Huang, Weijia Lin, Li Yan, Yanling Feng
Summary: Quantitative HBsAg is more valuable than HBV DNA in predicting significant hepatitis activity of HBeAg-positive chronic HBV infection, with higher sensitivity and specificity levels.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Yuki Tanaka, Shun Ishido, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Yuka Hayakawa, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Ryuichi Okamoto, Namiki Izumi
Summary: The aim of this study was to establish a target value of ALT level during NA treatment as a risk marker for HCC. The results showed that patients with ALT <21 IU/L at 1 year after NA initiation had a lower risk of HCC.
HEPATOLOGY RESEARCH
(2023)
Article
Virology
Yuki Takamatsu, Sanae Hayashi, Hiroki Kumamoto, Shuhei Imoto, Yasuhito Tanaka, Hiroaki Mitsuya, Nobuyo Higashi-Kuwata
Summary: This study investigated the effects of chronic HBV infection on cellular senescence in human hepatocytes and humanized-liver chimeric mice. The results showed that HBV infection perturbed multiple senescence-associated markers in both human hepatocytes and humanized-mice liver, while treatment with the anti-HBV drug E-CFCP restored this phenomenon.
Article
Immunology
Hong Zhang, Fengjiao Wang, Xiaoxue Zhu, Yunfu Chen, Hong Chen, Xiaojiao Li, Min Wu, Cuiyun Li, Jingrui Liu, Yingjun Zhang, Yanhua Ding, Junqi Niu
Summary: The study demonstrates that GLS4 has antiviral activity in treating patients with chronic HBV infection, and the 120 mg GLS4 treatment regimen shows good tolerability.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Virology
Yael Gozlan, Daniella Aaron, Yana Davidov, Maria Likhter, Gil Ben Yakov, Oranit Cohen-Ezra, Orit Picard, Oran Erster, Ella Mendelson, Ziv Ben-Ari, Fadi Abu Baker, Orna Mor
Summary: In this study, a comprehensive characterization of CHB patients was conducted to assess the cumulative impact of classical and novel biomarkers on clinical categorization. The results showed that the combined assessment of classical and novel serum biomarkers, especially in HBeAgNeg patients, may assist in clinical decisions.